| Title |
Intravenous immunoglobulin for myasthenia gravis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, December 2012
|
| DOI | 10.1002/14651858.cd002277.pub4 |
| Pubmed ID | |
| Authors |
Philippe Gajdos, Sylvie Chevret, Klaus V Toyka |
| Abstract |
Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission. As with other autoimmune diseases, people with myasthenia gravis would be expected to benefit from intravenous immunoglobulin (IVIg). This is an update of a review first published in 2003 and last updated in 2007. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 226 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | <1% |
| Colombia | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 222 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 26 | 12% |
| Student > Bachelor | 24 | 11% |
| Student > Master | 23 | 10% |
| Researcher | 21 | 9% |
| Student > Doctoral Student | 18 | 8% |
| Other | 58 | 26% |
| Unknown | 56 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 102 | 45% |
| Nursing and Health Professions | 14 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
| Agricultural and Biological Sciences | 9 | 4% |
| Biochemistry, Genetics and Molecular Biology | 7 | 3% |
| Other | 23 | 10% |
| Unknown | 61 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2021.
All research outputs
#4,208,412
of 22,953,506 outputs
Outputs from Cochrane database of systematic reviews
#6,674
of 12,333 outputs
Outputs of similar age
#43,647
of 279,978 outputs
Outputs of similar age from Cochrane database of systematic reviews
#93
of 192 outputs
Altmetric has tracked 22,953,506 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,333 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.6. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 192 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.